There is increasing evidence that abnormalities in epigenetic mechanisms of gene
expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have
given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are
being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that
inhibit DNA methyltransferase (DNMTi) and drugs that inhibit histone deacetylase (HDACi). This
paper discusses the potential use of epigenetic drugs in the treatment of MS, focusing on DNMTi and
HDACi. Preclinical drug trials of DNMTi and HDACi for the treatment of MS are showing promising
results. Epigenetic drugs could improve the clinical management of patients with MS.
Keywords: DNA methyltransferase inhibitor, epigenetic, histone deacetylase inhibitor, multiple sclerosis.
Rights & PermissionsPrintExport